Skip to main content
. 2008 Oct 1;46(11):3746–3751. doi: 10.1128/JCM.00612-08

FIG. 3.

FIG. 3.

Evolution of antibody titers of five representative patients measured by ELISA (OD values) and HCV RNA level during treatment. Patients 1, 2, and 3 are nonresponders (IFN-NR), and their anti-F protein antibody titer (patients 1, 2, and 3a) or anti-F99 peptide antibody titer (patient 3b) remained stable, as did their HCV RNA level. Patients 4 and 5 are responders (IFN-R), and their anti-F protein antibody titer (patients 4 and 5a) or anti-F99 peptide antibody titer (patient 5b) decreased gradually, as did their HCV RNA level. The anticore antibody levels did not significantly change in the two responders and three nonresponders during antiviral therapy The red, black, and yellow lines represent anti-F antibody titer, anticore antibody titer, and HCV RNA level, respectively. Anti-F-protein antibody titers 6 months after treatment (S/co) are shown on the right-hand y axes.